SARS-CoV-2 rapid antigen detection tests
Date
2021
Type:
Article
item.page.extent
item.page.accessRights
item.contributor.advisor
ORCID:
Journal Title
Journal ISSN
Volume Title
Publisher
item.page.isbn
item.page.issn
item.page.issne
item.page.doiurl
item.page.other
item.page.references
Abstract
Papers who discuss the benefits and limitations of SARS-CoV-2
antigen rapid detection tests (AgRDTs) for scaling up diagnostic capacities in different settings. As recent evaluations suggest, Ag-RDTs can reliably detect patients during the initial infective phase of COVID-19 (when patients have high viral loads). As the authors emphasise, the screening of asymptomatic individuals in low-prevalence settings is hampered by imperfect specificity. The dilemma that most detected cases represent false positives rather than true infections might require a twotier approach with molecular
confirmation, affecting the practicality and acceptance of such a strategy. Here we suggest alternative strategies to optimise the use of AgRDTs in asymptomatic populations with low positivity likelihood.
Description
item.page.coverage.spatial
item.page.sponsorship
Citation
Weitzel T, Pérez C, Tapia D, Legarraga P, Porte L. SARS-CoV-2 rapid antigen detection tests. Lancet Infect Dis. 2021 Aug;21(8):1067-1068. doi: 10.1016/S1473-3099(21)00249-8. Epub 2021 May 4. PMID: 33961799; PMCID: PMC8096320.
Keywords
Antigens, Viral, COVID-19 Testing, COVID-19, SARS-CoV-2